| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | -922,9 € | -1.3% | -910,8 € | -5.6% | -862,2 € | -75.0% | -492,6 € | +60.7% | -1,3 k € | -1.5% | -1,2 k € | +31.3% | -1,8 k € | -197.8% | -602,9 € | +59.4% | -1,5 k € | +93.8% | -24,0 k € | +48.0% | -46,1 k € | -237.2% | 33,6 k € | +19.3% | 28,2 k € | +291.1% | -14,7 k € | -41.8% | -10,4 k € | +46.4% | -19,4 k € | |
| EBITDA | -1,3 k € | +1.9% | -1,4 k € | -12.1% | -1,2 k € | -41.8% | -853,0 € | +46.7% | -1,6 k € | -29.6% | -1,2 k € | +42.4% | -2,1 k € | -125.5% | -950,4 € | +73.5% | -3,6 k € | +90.0% | -35,8 k € | +22.7% | -46,3 k € | -242.5% | 32,5 k € | +16.6% | 27,8 k € | +284.4% | -15,1 k € | -36.0% | -11,1 k € | +43.8% | -19,8 k € | |
| Operating profit | -1,3 k € | +1.9% | -1,4 k € | +48.0% | -2,6 k € | -15.8% | -2,3 k € | +24.9% | -3,0 k € | -13.9% | -2,6 k € | +70.4% | -8,9 k € | -4.2% | -8,5 k € | +33.4% | -12,8 k € | +71.5% | -45,0 k € | +18.9% | -55,5 k € | -335.3% | 23,6 k € | +5.1% | 22,4 k € | +211.7% | -20,1 k € | -24.8% | -16,1 k € | +35.0% | -24,8 k € | |
| Profit/loss | -1,8 k € | +0.9% | -1,8 k € | +40.5% | -3,1 k € | -14.4% | -2,7 k € | +19.2% | -3,4 k € | -14.7% | -2,9 k € | +68.4% | -9,3 k € | -5.6% | -8,8 k € | +34.4% | -13,4 k € | +68.9% | -43,0 k € | +23.1% | -55,9 k € | -471.1% | 15,1 k € | -32.5% | 22,3 k € | +210.1% | -20,3 k € | -24.2% | -16,3 k € | +34.6% | -25,0 k € | |
| Equity | -151,5 k € | -1.2% | -149,7 k € | -1.2% | -147,9 k € | -2.1% | -144,8 k € | -1.9% | -142,1 k € | -2.4% | -138,7 k € | -2.2% | -135,8 k € | -7.3% | -126,5 k € | -7.4% | -117,8 k € | -12.8% | -104,4 k € | -69.9% | -61,5 k € | -999.2% | -5,6 k € | +72.9% | -20,6 k € | +51.9% | -43,0 k € | -89.3% | -22,7 k € | -256.3% | -6,4 k € | |
| Total assets | 1,0 k € | -45.1% | 1,8 k € | -38.3% | 3,0 k € | -50.1% | 6,0 k € | -36.7% | 9,4 k € | -21.5% | 12,0 k € | -23.3% | 15,7 k € | -35.4% | 24,3 k € | -27.5% | 33,5 k € | -28.7% | 47,0 k € | -63.2% | 127,6 k € | -12.2% | 145,3 k € | +18.2% | 122,9 k € | +112.5% | 57,9 k € | -15.9% | 68,8 k € | +51.8% | 45,4 k € | |
| Cash | 484,4 € | -63.1% | 1,3 k € | -55.9% | 3,0 k € | -34.8% | 4,6 k € | -31.2% | 6,6 k € | -15.2% | 7,8 k € | -22.3% | 10,1 k € | -10.2% | 11,2 k € | -13.6% | 13,0 k € | -26.0% | 17,6 k € | +23452.6% | 74,6 € | +441.9% | 13,8 € | -99.8% | 5,5 k € | +887.6% | 559,3 € | +233.9% | 167,5 € | +99.0% | 84,2 € | |
| Debts | 152,6 k € | +0.7% | 151,6 k € | +0.5% | 150,9 k € | +0.1% | 150,8 k € | 0.0% | 150,8 k € | 0.0% | 150,8 k € | -0.5% | 151,5 k € | +0.4% | 150,8 k € | -0.3% | 151,3 k € | -0.1% | 151,4 k € | -19.9% | 189,0 k € | +25.4% | 150,8 k € | +5.0% | 143,6 k € | +42.4% | 100,8 k € | +10.7% | 91,1 k € | +76.1% | 51,7 k € | |
Source: Belgian Official Gazette
Private company with limited liability · Eupen · incorporated on 28/05/2009
Private company with limited liability loss-making in the latest fiscal year. Cash position declining (-63.1%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
PLUS PHARMA is a Private company with limited liability incorporated in 2009. Its registered office is in Eupen.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.